Clinical trials
for patients

The primary objective is to compare the clinical efficacy of Rina-S with the investigator’s choice (IC) of treatment in patients with recurrent or progressive endometrial cancer (EC) following prior treatment.

The primary objective is to compare sac-TMT maintenance therapy with or without bevacizumab against standard of care (SoC) in terms of PFS as defined by RECIST 1.1, as assessed by the BICR.

You are invited to participate in this study because you have metastatic lung cancer. To participate in this study, your lung cancer must express a protein called programmed death-ligand 1 (PD-L1). PD-L1 is a protein found on cancer cells that can prevent the body’s immune system from attacking the cancer cells. Pembrolizumab is a treatment that blocks the effects of PD-L1 and allows the immune system to attack and kill cancer cells. Your disease must have a PD-L1 score of ≥50%. This re...

The aim of this research study is to test a new treatment for a specific type of stomach cancer. It is intended for people whose cancer cells express certain proteins (claudin 18.2 and PD-L1) and do not express another protein called HER2

The purpose of this study is to learn more about the effectiveness and safety of the study drug, volrustomig (also known as MEDI5752), when given in combination with a standard treatment for colorectal cancer.

The purpose of this study is to determine the highest dose of BI 3819026 that people with advanced cancer can tolerate when taken alone and in combination with ezabenlimab.

The trial consists of 3 parts. The objective of Part 1 is to assess the safety of GEN1079 at increasing doses and to identify the doses to be used in subsequent phases. The objective of Part 2 is to refine and identify the dose that is effective while causing the fewest side effects. The goal of Part 3 is to further investigate whether GEN1079 works against the tumor and how it does so, and to continue learning about its side effects.

The goal is to continuously monitor your well-being and safety, and to ask you if you have started a new treatment. If, for any reason, the doctor or trial staff are unable to contact you, a family member may provide information about your condition, or the trial doctor may obtain it from sources such as your medical records, national or local registries, or publicly available information, as permitted by local regulations.

The main objective of this study is to compare disease-free survival (DFS) between patients receiving TAR-210 and investigator-selected intravesical chemotherapy.

The main objective is to evaluate the safety and tolerability of IMC-P115C as monotherapy and in combination in participants with PRAME-positive advanced tumors, and to identify the MTD (maximum tolerated dose) and dosing regimens (combination of IMC-P115C dose, dosing frequency, and premedication) for further optimization.